Drug Profile
Research programme: peptide therapeutics - Bayer/PeptiDream
Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Bayer; PeptiDream
- Class Antineoplastics; Cardiovascular therapies; Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Cardiovascular disorders
Most Recent Events
- 06 Dec 2022 Preclinical trials in Cancer in Germany (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Cancer in Japan (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Cardiovascular disorders in Germany (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)